 |
|
Press Releases
|
January 8, 2010 |
Dr. Mark W. Schwartz joins Apthera as President & CEO |
|
|
October 9, 2009 |
Investment Banking Executive Ira Z. Leiderman and Dr. Mary Ann Gray join the Board of Directors at Apthera, Inc.
|
|
|
June 25, 2009 |
Apthera Receives Special Protocol Assessment (SPA) From FDA for Pivotal Phase III Trial of NeuVax in Early-Stage Breast Cancer |
|
|
June 4, 2009 |
Apthera Announces Product License Agreement with Kwang Dong Pharmaceutical Co., Ltd. |
|
|
December 9, 2008 |
Apthera Announces Phase III and Commercial Drug Formulation for NeuVax™ |
|
|
October 1, 2008 |
Apthera Announces Optimal Dose and Schedule of NeuVax for Phase III Clinical Trial in Breast Cancer |
|
|
August 5, 2008 |
Apthera and TGen Drug Development Services (TD2) Sign Master Services Agreement |
|
|
June 2, 2008 |
Apthera’s NeuVax™ Produces Delays in Recurrence in High-Risk HER2-Positive Prostate Cancer Patients |
|
|
April 14, 2008 |
Low HER2 Expressing Breast Cancer Patients Respond Preferentially to Apthera’s NeuVax™ |
|
|
October 31, 2007 |
Apthera Announces Completion of End of Phase II Meeting with the U.S. Food and Drug Administration for NeuVax™ for Breast Cancer |
|
|
